We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Patrick Thomas
Regeneron Pharmaceuticals Inc. (REGN) said its profit rose for its third quarter as revenue grew 23% from a year earlier.
The pharmaceutical company reported a profit of $669.6 million, or $5.86 a share, compared with $594.7 million, or $5.17 a share, a year ago.
The company reported adjusted earnings of $6.67 a share. Analysts polled by FactSet were expecting earnings of $5.71 a share, or $6.40 a share on an adjusted basis.
Revenue rose to $2.05 billion from $1.66 billion a year earlier. Analysts had expected $1.99 billion of revenue in the quarter.
U.S. net sales of the company's Eylea drug increased 16% to $1.19 billion for the quarter, the company said.
Write to Patrick Thomas at patrick.thomas@wsj.com
(END) Dow Jones Newswires
November 05, 2019 06:59 ET (11:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
